Century Therapeutics, Inc. (IPSC) vs X4 Pharmaceuticals, Inc. (XFOR)

Century Therapeutics, Inc. and X4 Pharmaceuticals, Inc. are both Biotechnology companies. Century Therapeutics, Inc. and X4 Pharmaceuticals, Inc. are of similar size ($306.0M and $297.4M). Century Therapeutics, Inc. grew revenue faster over the last twelve months: 8,286.7% against −51.7%. Century Therapeutics, Inc. has the higher net margin (0.00% vs −568.8%) and the higher return on invested capital (−64.9% vs −226.6%). Across the 17 metrics below, Century Therapeutics, Inc. leads on 13 and X4 Pharmaceuticals, Inc. on 4.

Valuation

Metric IPSC XFOR Biotechnology median
P/E n/m n/m 7.88
P/S 2.99 24.00 11.47
P/B 1.48 2.45 2.52
Price to free cash flow n/m 23.86 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1.95 15.77 10.73
Earnings yield (55.69%) (39.87%) (28.84%)
Free cash flow yield (25.62%) 4.19% (23.03%)

Profitability

Metric IPSC XFOR Biotechnology median
Gross margin 100.00% 81.51% 65.16%
Operating margin 0.00% (554.71%) 0.00%
Net margin 0.00% (568.80%) 0.00%
Free cash flow margin 0.00% (559.95%) 0.00%
Return on equity (49.65%) (113.08%) (57.72%)
Return on assets (38.41%) (50.32%) (49.22%)
Return on invested capital (64.92%) (226.62%) 0.00%

Growth

Metric IPSC XFOR Biotechnology median
Revenue growth (TTM) 8,286.72% (51.65%) 5.64%
EPS growth (last fiscal year) 93.12% 67.23% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IPSC XFOR Biotechnology median
Debt to equity 0.00 0.49 0.00
Current ratio 8.28 11.30 4.73
Net debt to EBITDA 17.95 2.06 0.96

Dividend

Metric IPSC XFOR Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IPSC XFOR Biotechnology median
Market cap 306.02m 297.44m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack